



SPR Therapeutics

April 17, 2018

Attention: Application Examiner

RE: Request for Confidentiality
Applicant: SPR Therapeutics, Inc.
FCC ID: 2AO2X-9620

To Whom It May Concern:

Request is hereby submitted by SPR Therapeutics, Inc. to withhold permanently from public review certain portions of the application for equipment certification for the referenced FCC identifiers. This request for confidentiality is made pursuant to 47 CFR 0.457(d) and 0.459 of the FCC Rules. In particular, the following sections of the application are to be kept permanently confidential:

- Schematics – (8025-SCH-000 Handheld Remote Schematic)
- Detailed Block Diagrams (Handheld Remote Block Diagram)
- Detailed Operational/Functional Description - (Handheld Remote Operational Description)
- Internal photos – Device is not sold to end users
- User Manual - Clinician Manual (L0090-MAN-000) is only intended for specially trained personnel and the device is non-serviceable

Additionally, request is hereby submitted by SPR Therapeutics to withhold from public review for a period of 180 days from the date of the Grant of Equipment Authorization and prior to marketing, certain portions of the application for equipment certification for the referenced FCC identifiers. This request for confidentiality is made pursuant to 47 CFR 0.457(d) and 0.459 of the FCC Rules. In particular, the following sections of the application are to be kept confidential for a period of 180 days from the date of Authorization:

- External photos
- User manual – Patient Manual (L0092-MAN-000)

Rationale for request for confidentiality:

SPR Therapeutics, Inc. has invested considerable time and materials in research and development to produce the referenced product. The documents listed above contain trade secrets and are considered confidential. Disclosure of the permanently confidential portions of this application to competitors would not only give them significant competitive advantages in developing similar products, but would also disclose successful implementation of unpublished, leading edge technology developed by us, causing SPR Therapeutics, Inc. financial damage. Disclosure of the short-term confidential portions of this application during the period of importation and/or distribution would reveal key aspects of proprietary technology to competitors and diminish the value of our investment in research and development.

If you have questions or need further information, please contact the undersigned.

Sincerely,

Matt Wunzin
Product Design Engineer
SPR Therapeutics